Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 495-501

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Kajiwara, Eiji ^b   Takahashi, Kazuhiro ^c   Nomura, Hideyuki ^d   Maruyama, Toshihiro ^e   Tanabe, Yuichi ^f   Satoh, Takeaki ^g   Nakamuta, Makoto ^h   Kotoh, Kazuhiro ⁱ   Azuma, Koichi ^j   Dohmen, Kazufumi ^k   Shimoda, Shinji ⁱ   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

^d Shin Kokura Hospital   (Japan)

^e KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^f Fukuoka City Hospital   (Japan)

^g Kokura Medical Center   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j Kyushu Central Hospital   (Japan)

^k CHIHAYA HOSPITAL   (Japan)

more..

Author keywords

Hepatitis C; Hepatocellular carcinoma; Pegylated interferon; Ribavirin

Indexed keywords

(REBETOL;; ALPHA FETOPROTEIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER RISK; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK ASSESSMENT; SEX RATIO; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84874117560     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.017     Document Type: Conference Paper

References (35)

1. J. Hayashi, N. Furusyo, I. Ariyama, Y. Sawayama, Y. Etoh, and S. Kashiwagi A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia J Infect Dis 181 2000 1523 1527
2. L.B. Seeff, Z. Buskell-Bales, E.C. Wright, S.J. Durako, H.J. Alter, and F.L. Iber Long-term mortality after transfusion-associated non-A, non-B hepatitis N Engl J Med 327 1992 1906 1911
3. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
4. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
5. F. Kanwal, T. Hoang, J.R. Kramer, S.M. Asch, M.B. Goetz, and A. Zeringue Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection Gastroenterology 140 2011 1182 1188
6. S. Nishiguchi, T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, and S. Nakajima Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
7. G. Mazzella, E. Accogli, S. Sottili, D. Festi, M. Orsini, and A. Salzetta Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 1996 141 147
8. Y. Imai, S. Kawata, S. Tamura, I. Yabuuchi, S. Noda, and M. Inada Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
9. H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, and M. Sata Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 174 181
10. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonçales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
11. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
12. N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, Y. Tanabe, and A. Masumoto Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients J Gastroenterol Hepatol 23 2008 1094 1104
13. T.R. Morgan, M.G. Ghany, H.Y. Kim, K.K. Snow, M.L. Shiffman, and J.L. De Santo Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
14. Y. Tanaka, K. Hanada, M. Mizokami, A.E. Yeo, J.W. Shih, and T. Gojobori A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades Proc Natl Acad Sci U S A 99 2002 15584 15589
15. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
16. E. Ogawa, N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, and Y. Tanabe Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection J Gastroenterol Hepatol 27 2012 1233 1240
17. M. Kainuma, N. Furusyo, K. Azuma, E. Kajiwara, K. Takahashi, and H. Nomura Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase Hepatol Res 42 2012 33 41
18. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
19. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C Hepatology 20 1994 15 20
20. C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526
21. E. Ogawa, N. Furusyo, K. Toyoda, H. Takeoka, S. Maeda, and J. Hayashi The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin Antiviral Res 83 2009 127 134
22. European Association of the Study of the Liver 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines Liver Int 32 2012 2 8
23. P. Simmonds, A. Alberti, H.J. Alter, F. Bonino, D.W. Bradley, and C. Brechot A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology 19 1994 1321 1324
24. E. Vittinghoff, and C.E. McCulloch Relaxing the rule of ten events per variable in logistic and Cox regression Am J Epidemiol 165 2007 710 718
25. A.S. Lok, J.E. Everhart, E.C. Wright, A.M. Di Bisceglie, H.Y. Kim, and R.K. Sterling Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C Gastroenterology 140 2011 840 849
26. J. Bruix, T. Poynard, M. Colombo, E. Schiff, K. Burak, and E.J. Heathcote Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 2011 1990 1999
27. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
28. A.A. Butt, and F. Kanwal Boceprevir and telaprevir in the management of hepatitis C virus-infected patients Clin Infect Dis 54 2012 96 104
29. A. Kasahara, N. Hayashi, K. Mochizuki, M. Takayanagi, K. Yoshioka, and S. Kakumu Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1998 1394 1402
30. Y. Shiratori, Y. Ito, O. Yokosuka, F. Imazeki, R. Nakata, and N. Tanaka Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 2005 105 114
31. F. Imazeki, O. Yokosuka, K. Fukai, and H. Saisho Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study Hepatology 38 2003 493 502
32. J. Fung, C.L. Lai, and M.F. Yuen Hepatitis B and C virus-related carcinogenesis Clin Microbiol Infect 15 2009 964 970
33. G. Nkontchou, J.P. Bastard, M. Ziol, M. Aout, E. Cosson, and N. Ganne-Carrie Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis J Hepatol 53 2010 827 833
34. E. Ogawa, N. Furusyo, M. Murata, H. Ikezaki, T. Ihara, and T. Hayashi Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1 J Hepatol 57 2012 534 540
35. E. Bugianesi, F. Salamone, and F. Negro The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 2012 S56 S65